Molecular Modeling, Synthesis, and Antihyperglycemic Activity of the New Benzimidazole Derivatives – Imidazoline Receptor Agonists
Artur Martynov,Boris Farber,Tatyana Bomko,Daniel L Beckles,Ilya Kleyn,Daniel Beckles
DOI: https://doi.org/10.2147/dddt.s447289
IF: 4.3188
2024-04-04
Drug Design Development and Therapy
Abstract:Artur Martynov, 1 Boris Farber, 2 Tatyana Bomko, 1 Daniel L Beckles, 3 Ilya Kleyn 4 1 Laboratory and Clinical department of Molecular Immunopharmacology, SI " I. Mechnikov Institute of Microbiology and Immunology of National Academy of Medical Sciences of Ukraine, Kharkiv, Ukraine; 2 R&D Department, Noigel LLC, New York, NY, USA; 3 Baylor Scott & White Health, Round Rock, TX, USA; 4 SUNY Downstate Medical Center / University Hospital of Brooklyn, New York, NY, USA Correspondence: Artur Martynov, Email Introduction: The paper presents the results of a study on the first synthesized benzimidazole derivatives obtained from labile nature carboxylic acids. The synthesis conditions of these substances were studied, their structure was proved, and some components were found to have sugar-reducing activity on the model of alloxan diabetes in rats. Methods: The study used molecular modeling methods such as docking based on the evolutionary model (igemdock), RP_HPLC method to monitor the synthesis reaction, and 1H NMR and 13C NMR, and other methods of organic chemistry to confirm the structures of synthesized substances. Results & Discussion: The docking showed that the ursodeoxycholic acid benzimidazole derivatives have high tropics to all imidazoline receptor carriers (PDB ID: 2XCG, 2bk3, 3p0c, 1QH4). The ursodeoxycholic acid benzimidazole derivative and arginine and histidine benzimidazole derivatives showed the highest sugar-lowering activity in the experiment on alloxan-diabetic rats. For these derivatives, the difference in glucose levels of treated rats was significant against untreated control. Therefore, the new derivatives of benzimidazole and labile natural organic acids can be used to create new classes of imidazoline receptor inhibitors for the treatment of diabetes mellitus and hypertension. Keywords: imidazoline receptors, benzimidazole derivatives, synthesis, antihyperglycemic activity Research interest in imidazoline receptor (IR) agonists has recently increased. This is because the selective I 1 -imidazoline receptor (I 1 R) agonist moxonidine, 1,2 the selective I 2 -imidazoline receptor (I 2 R) agonists diakamph 3 and metformin 4 have been found to have the ability to stimulate telomerase expression in cells and exhibit the ability to inhibit senescence. In addition, the apparent ability of diakamph (V), moxonidine (VI), and metformin to increase tissue sensitivity to insulin has been shown. All three substances have been successfully used as medicines. Metformin is used as a treatment for diabetes mellitus, and moxonidine (VI) is a centrally-acting hypotensive drug (Figure 1). Particular attention should be paid to I 3 -imidazoline receptors (I 3 R), which are found in the pancreas and stimulated, leading to increased insulin production by beta-cells. 5 Figure 1 Synthesis of some benzimidazole derivatives (IVa-f). I 1 Rs are associated with phosphatidylcholine hydrolysis, the formation of arachidonic acid and eicosanoids, and are actively associated with catecholamine synthesis. Some studies indicate that I1Rs belong to neurocytokine receptors and are similar in action to interleukins. 6–8 I 1 Rs are located in the brainstem and modulate blood pressure. In peripheral tissues, I 1 Rs are found in the kidneys and are associated with regulating sodium balance in the body. 9 In the human brain, I 1 Rs are concentrated in the triatum, pale globe, and substantia nigra. 7 The activation of I 1 Rs also negatively regulates the progression of fibrosis in hepatic stellate cells through a Nrf2-dependent pathway. This hepatic I1-dependent antifibrotic action was also observed in vivo in mice. 10 Imidazoline Subtype 1 receptors have been shown to affect insulin and adiponectin positively. A study using insulin-secreting Min6 b-cells found that activation of I1Rs with a selective I1 receptor ligand, S43126, had a glucose-dependent insulinotropic action. 11 This effect was prevented by efaroxan, a selective I 1 Rs antagonist. Similarly, it was also demonstrated that activating I1Rs on insulin-targeted tissues such as liver and adipose tissues improved insulin sensitivity. 12 LNP599, a highly selective I 1 Rs compound, stimulates adiponectin secretion in 3T3-L1 adipocyte cultures. 13 In human platelets, dexmedetomidine, an alpha-2 adrenergic agonist and I1Rs agonist suppressed ADP-induced platelet aggregation when alpha-2 adrenergic receptors were blocked by yohimbine. This specific activation of I 1</su -Abstract Truncated-
pharmacology & pharmacy,chemistry, medicinal